Estrella Biopharma develops CD19-Redirected ARTEMIS T Cells for T-cell immunotherapy to target and eliminate cancer cells. This technology aims to improve patient outcomes by enhancing the efficacy of cancer treatments and addressing the limitations of current therapies.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current T-cell immunotherapies face challenges in effectively targeting and eliminating cancer cells, leading to suboptimal patient outcomes. Existing treatments may not be potent enough or may have limitations in reaching and penetrating tumors, hindering their ability to eradicate the disease.
Solution
Estrella Biopharma is developing CD19-Redirected ARTEMIS T-cells to enhance T-cell immunotherapy for cancer treatment. This technology aims to improve the efficacy of targeting and eliminating cancer cells by redirecting the T-cells to specifically recognize and attack CD19-expressing cancer cells. By enhancing the precision and potency of T-cell therapies, Estrella Biopharma seeks to overcome the limitations of current treatments and improve patient outcomes in cancer immunotherapy. The ARTEMIS technology is designed to improve T-cell persistence and reduce exhaustion, leading to a more durable anti-tumor response.
Target Audience
The primary target audience includes patients with CD19-positive cancers, as well as oncologists and medical professionals seeking advanced T-cell immunotherapy options.
Features
- CD19-Redirected ARTEMIS T-cells for targeted cancer cell elimination
- Enhanced T-cell persistence and reduced exhaustion for durable anti-tumor response
- Improved targeting precision for CD19-expressing cancer cells
- ARTEMIS technology platform for enhanced T-cell immunotherapy